Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donationsO형 회복기 혈장 기증은 A형 기증에 비해 SARS-CoV-2 IgG 항체 수치가 현저히 낮습니다.Article Published on 2021-08-012022-09-11 Journal: Transfusion [Category] MERS, SARS, 진단, 치료법, [키워드] Abbott ABO ABO blood group age antibody Antibody Response Antibody titer authorization Blood Blood Group CCP collected convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma determine distribution donation Donor Emergency evaluated FDA high-titer CCP IgG antibodies IgG antibody immunoassay individual less Microparticle no difference no significant difference no significant differences nucleocapsid nucleocapsid protein other blood group Patient plasma promote recruitment restrict SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibody SARS-COV-2 infection semi-quantitative Sex significantly lower subsequent symptom resolution unit was used [DOI] 10.1111/trf.16524 PMC 바로가기 [Article Type] Article
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19초기의 후기 회복기 혈장은 중등도에서 세상에서 더 나은 생존과 관련이 있습니다.Research Article Published on 2021-07-282022-09-10 Journal: PLoS ONE [Category] MERS, SARS, 임상, [키워드] addressed administration administration of CCP Analysis CCP CCP administration Cohort Complete conducted convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma COVID-19 infection days alive discharge disease Endpoint Follow-up had more hospital hospital discharge Hospital mortality Hospital stay IMPROVE in-hospital mortality Inpatient investigated likelihood Limited mechanical ventilation median moderate-to-severe COVID-19 Mortality on mechanical ventilation outcome Patient plasma primary endpoint primary endpoints Propensity score question receive recipient recipients Research question Result secondary Secondary endpoints Study design survival therapeutic therapeutic option transfused trials ventilator WHO [DOI] 10.1371/journal.pone.0254453 PMC 바로가기 [Article Type] Research Article
Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasmaCOVID-19 회복기 혈장의 면역학적 특성에 대한 병원체 감소 방법의 영향Article Published on 2021-07-012022-09-12 Journal: Vox Sanguinis [Category] SARS, 진단, [키워드] Amotosalen collected comparison convalescent convalescent plasma COVID-19 COVID-19 convalescent donor COVID-19 convalescent plasma decrease dose greater Immunoglobulin immunological Impact initial likelihood material Methylene blue N-protein Neutralizing activity neutralizing antibody NtAbs pathogen Pathogen reduction plasma provide RBD reduced reduction remained Riboflavin riboflavin. SARS-CoV-2 SARS-CoV2 specific antibody statistically significant titre Treatment virus were measured [DOI] 10.1111/vox.13056 PMC 바로가기 [Article Type] Article
Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey studyArticle Published on 2021-06-012023-07-13 Journal: Transfusion medicine (Oxford, England) [Category] SARS, [키워드] barriers Blood donors COVID-19 convalescent plasma Motivations pandemic [DOI] 10.1111/tme.12753
Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in IndiaCOVID-19 회복기 혈장 기증자 모집 억제: 인도 병원 기반 혈액 센터의 경험Article Published on 2021-06-012022-09-11 Journal: Transfusion medicine (Oxford, England) [Category] SARS, 치료기술, 치료제, [키워드] absence adopted analysed approach Blood blood donation CCP clinician convalescent plasma COVID-19 COVID-19 antibody COVID-19 convalescent plasma COVID-19 convalescent plasma (CCP) donors deferrals detectable deterrents Donor donor motivation donor recruitment. Donor selection donors Evidence experience fear female Health highlight hospital India information initial material medical examination multiparity multiparous Not completed pandemic Potential present recruited recruitment Retrieval scientific evidence telephone Total was obtained Whole blood [DOI] 10.1111/tme.12768 PMC 바로가기 [Article Type] Article
Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potencyCOVID-19 회복기 혈장 효능에 대한 병원체 감소 기술의 영향Editorial Published on 2021-05-012022-09-12 Journal: Transfusion clinique et biologique : journal de la [Category] 진단, [키워드] Concentration convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma COVID19 detrimental Efficacy Evidence IgG IgG subclasses Impact Infection lack NAb Neutralizing antibodies neutralizing antibody Pathogen inactivation Pathogen reduction technologies. reduction regulatory authority residual risk while [DOI] 10.1016/j.tracli.2021.02.005 PMC 바로가기 [Article Type] Editorial
High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients회복기 혈장에서 높은 수준의 일반적인 감기 코로나바이러스 항체는 COVID-19 환자의 생존율 향상과 관련이 있습니다Clinical Trial Published on 2021-04-282022-08-13 Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, [키워드] Administered age Anderson Cancer Center anti-HCoV-HKU1 spike IgG anti-HCoV-OC43 anti-HCoV-OC43 spike IgG anti-SARS-CoV-2 antibodies antibody antibody levels Antigen antigens association Bayesian Bayesian exponential survival time regression model Cancer patients CCP CCP administration Cold common common cold convalescent plasma coronavirus coronavirus antibodies coronavirus strains COVID-19 COVID-19 convalescent plasma COVID-19 infection COVID-19-related complications died domain early stage effective Factor female HCoV-HKU1 HCoV-OC43 HKU1 Hospitalized identify IgG antibodies Improved Level MD Anderson Cancer Center median age moderate moderate to severe monoclonal antibody non-SARS-CoV-2-specific antibodies OC43 Other other coronaviruses outcomes Patient PBE PBEs posterior probability prognostic variable prognostic variables quantified Regression model Result Safe SARS-CoV-2 SARS-CoV-2-specific antibody Severe COVID-19 Infection Sex specific antibodies specific antibody spike IgG survival survival time the disease therapeutic target [DOI] 10.3389/fimmu.2021.675679 PMC 바로가기 [Article Type] Clinical Trial
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray코로나바이러스 항원 마이크로어레이로 밝혀진 코로나바이러스 회복기 혈장의 뚜렷한 SARS-CoV-2 항체 반응성 패턴Article Published on 2021-04-062022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 진단, [키워드] acute COVID-19 Adaptive immunity administration analyses Analysis analyzed antibody reactivity Antibody Response Antibody responses Antigen antigens array assays CCP chemiluminescence immunoassay clinical Clinical studies Cluster Clustering analysis collected Computational approaches Concordance convalescent plasma coronavirus COVID-19 case COVID-19 cases COVID-19 convalescent plasma Cutoff disease Donor Emergency use EUA FDA Generalized linear model Hierarchical Hierarchical clustering analysis Humoral immunity identify immunoassay Immunoglobulin IMPROVE Infection intensity MERS Microarray multiplex neutralization Neutralization assay offer plasma plasma sample plasma samples positive Predictive pseudovirus random Random forest reactive reactivity reactivity pattern recombinant proteins reporter Result SARS-1 SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV2 serum specimen the SARS-CoV-2 therapeutic efficacy threshold thresholds Total total Ig training set Treatment vaccination vaccine immunogenicity Viral viral particle was used with COVID-19 [DOI] 10.1038/s41598-021-87137-7 PMC 바로가기 [Article Type] Article
Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults우리 국가를 위한 수동 면역 시험(PassITON): 입원한 성인에서 COVID-19 회복기 혈장을 평가하는 무작위 위약 대조 임상 시험을 위한 연구 프로토콜Study Protocol Published on 2021-03-202022-09-10 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 1:1 7-category ordinal scale activity Administered adults hospitalized blinded chimeric Clinical efficacy clinical status clinical trial clinical trials conducted convalescent plasma coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma COVID-19 patient daily living demonstrated detect Efficacy eligible Evidence Hospitalized include indicated less moderate moderate to severe Mortality multicenter nation Neutralizing antibodies neutralizing function normal activities Odds ratio Ordinal Scale oxygen oxygen-free days pandemic Pandemics Pass Passive passive immunity Patient placebo-controlled plasma Primary outcome Randomized randomized clinical trial Randomized controlled trial respiratory Respiratory Support respiratory symptom respiratory symptoms robust SARS-CoV-2 SARS-CoV-2: convalescent plasma secondary outcome severe COVID-19 Study protocol supplementary material symptomatic disease These data Treatment treatment of COVID-19 patients Trial Trial registration USA Viral Virus neutralization with COVID-19 [DOI] 10.1186/s13063-021-05171-2 PMC 바로가기 [Article Type] Study Protocol
Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma코로나19 회복기 혈장을 이용한 SARS-CoV-2 스파이크 단백질 매개 세포-세포 융합 차단Article Published on 2021-03-102022-09-01 Journal: Scientific Reports [Category] SARS, 변종, 임상, 진단, 치료기술, [키워드] blocking activity convalescent plasma COVID-19 COVID-19 convalescent plasma COVID-19 pandemic cross-neutralize effector cell effector cells Emerging infectious disease examined exhibit global public health immunology Infectious disease inhibit interactions involved membrane fusion Microbiology molecular mechanism molecular mechanisms neutralizing antibody S protein SARS-CoV infections SARS-CoV-2 SARS-CoV-2 S protein SARS-CoV-2 spike SARS-CoV-2-S target cells the SARS-CoV-2 therapeutic therapeutic agent titers of IgG to define virus virus entry [DOI] 10.1038/s41598-021-84840-3 PMC 바로가기 [Article Type] Article